成纖維細(xì)胞生長(zhǎng)因子23(FGF23)活性蛋白
Active Fibroblast Growth Factor 23 (FGF23)
ADHR; HYPF; HPDR2; PHPTC; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor
- 編號(hào)APA746Ra01
- 物種Rattus norvegicus (Rat,大鼠) 相同的名稱(chēng),不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)10.0
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 2203 ¥ 5508 ¥ 11016 ¥ 33048 ¥ 82620
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
活性實(shí)驗(yàn)
Fibroblast growth factor 23 or FGF23 is a member of the fibroblast growth factor (FGF) family which is responsible for phosphate and vitamin D metabolism. The main function of FGF23 seems to be regulation of phosphate concentration in plasma. FGF23 decreases the reabsorption and increases excretion of phosphate and suppress 1-alpha-hydroxylase, reducing its ability to activate vitamin D and subsequently impairing calcium absorption. Besides, Fibroblast Growth Factor Receptor 4 (FGFR4) has been identified as an interactor of FGF23, thus a binding ELISA assay was conducted to detect the interaction of recombinant rat FGF23 and recombinant rat FGFR4. Briefly, FGF23 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100μl were then transferred to FGFR4-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-FGF23 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50μL stop solution to the wells and read at 450nm immediately. The binding activity of FGF23 and FGFR4 was shown in Figure 1, and this effect was in a dose dependent manner.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月,-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Rattus norvegicus (Rat,大鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA746Ra01 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA746Ra01 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)活性蛋白 | Cell?culture;?Activity?Assays. |
PAA746Ra01 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)多克隆抗體 | WB; IHC; ICC; IP. |
MAA746Ra21 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)單克隆抗體 | WB; IHC; ICC; IP. |
SEA746Ra | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
CEA746Ra | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA746Ra | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
KSA746Ra11 | 成纖維細(xì)胞生長(zhǎng)因子23(FGF23)檢測(cè)試劑盒DIY材料(酶聯(lián)免疫吸附試驗(yàn)法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Journal of international medicine | Prognostic impact of renal function in precapillary pulmonary hypertension [Pubmed: 24011362] |
BMC Nephrology | FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients [Pubmed: 24180481] |
Journal of Clinical Densitometry | Lower Fibroblast Growth Factor 23 Levels in Young Adults With Crohn Disease as a Possible Secondary Compensatory Effect on the Disturbance of Bone and Mineral Metabolism [Pubmed: 23623649] |
J Intern Med. | Prognostic impact of renal function in precapillary pulmonary hypertension. [Pubmed:24011362] |
Journal of Bone and Mineral Research | Adverse effects of osteocytic constitutive activation of ?-catenin on bone strength and bone growth [Pubmed:25639729] |
Nefrologia | Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation El factor de crecimiento fibroblástico está asociado con el índice de masa ventricular izquierda, anemia y niveles bajos de saturación de la transferrina [PubMed: 26394828] |
Medicine (Baltimore) | An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic Cancer [PubMed: 26266370] |
Ann Biol Clin (Paris) | Les biomarqueurs des calcifications vasculaires: quelles limites analytiques pour leur transfert de la recherche bioclinique à la pratique? [PubMed: 26069069] |
Scandinavian Journal of Gastroenterology | High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23 [Pubmed:27326766] |
PLOS?ONE | Prostaglandin-E2?Mediated?Increase?in?Calcium?and?Phosphate?Excretion?in a?Mouse?Model?ofDistal?Nephron?Salt?Wasting. [pubmed:27442254] |
Journal of Laboratory Diagnostics | Evaluation of concentration fibroblast growth factor FGF-23 in hemodialysed patients and after kidney transplantation [publication:312592751] |
Journal of Integrative Nephrology & Andrology | Associations between serum fibroblast growth factor 23 level and intradialytic hypotension in hemodialysis patients [issn:2394-2916] |
Journal of Renal Nutrition | ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder. [pubmed:29056164] |
Experimental Biology and Medicine(Maywood) | Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats [Pubmed:29763365] |
Psychiatry Research | Cerebrospinal fluid FGF23 levels correlate with a measure of impulsivity [Pubmed:29677623] |
BMC?Pediatrics | Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children [Pubmed:29907141] |
Medical Science Monitor | Effect of Salt Intervention on Serum Levels of Fibroblast Growth Factor 23 (FGF23) in Chinese Adults: An Intervention Study [Pubmed:29608553] |
International Journal of Chronic Obstructive Pulmonary Disease | Disconnection of pulmonary and systemic arterial stiffness in COPD [Pubmed:29881265] |
Saudi?journal of?kidney?diseases and transplantation | Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patients [Pubmed:29970732] |
Nephrology Dialysis?Transplantation | High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease [Pubmed: 30189026] |
BioFactors? | Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma [Pubmed: 30334297] |
Biological?Trace?Element?Research | Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients [Pubmed: 30847765] |
Clin Implant Dent Relat Res. | Evaluation of FGF‐23 and 25(OH)D3 levels in peri‐implant sulcus fluid in peri‐implant health and diseases [Pubmed: 31407857] |
JACC-Cardiovascular Imaging | PREVALANCE AND PROGRESSION OF CARDIOVASCULAR CALCIFICATIONS IN HAEMODIALYSIS PATIENTS [Pubmed: 28797410] |
Saudi J Kidney Dis Transpl | Serum fibroblast growth factor 23 levels do not correlate with carotid intima-media thickness in patients with chronic kidney disease [Pubmed: 31696838] |
Biomedicine & Pharmacotherapy | MiRNA-192-5p attenuates airway remodeling and autophagy in asthma by targeting MMP-16 and ATG7 [Pubmed: 31918268] |
Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis? [] | |
THE RELATIONSHIP BETWEEN ARTERIAL STIFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS [] | |
THE RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS KRON?K ?- [] | |
Calcif Tissue Int | The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations [Pubmed:35665817] |
European Journal of Medical Genetics | Genetic and clinical profile of patients with hypophosphatemic rickets [Pubmed:35738466] |
African Health Sciences | Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease [] |